title: Asthma and Atopic Dermatitis: A Review of Targeted Inhibition of Interleukin-4 and Interleukin-13 As Therapy for Atopic Disease.
abstract: Type 2 helper T cell (Th2)-mediated inflammation plays a critical role in the pathogenesis of allergic asthma and atopic dermatitis (AD). Recent research focusing on the suppression of the Th2 axis with targeted inhibitors in atopic disease is showing promising early results. In particular, the simultaneous blockage of interleukin (IL)-4 and IL-13 has successfully mitigated symptoms of allergic asthma and AD in preliminary clinical trials. Given the current therapeutic challenges of treating these chronic and severe diseases, this review brings to light new data demonstrating that agents targeting IL-4 and IL-13 are relatively safe and effective medications in blocking the inflammatory cascade responsible for allergic asthma and atopic dermatitis.
authors.forename: Catherine D
authors.initials: CD
authors.lastname: Buzney
authors.forename: Alice B
authors.initials: AB
authors.lastname: Gottlieb
authors.forename: David
authors.initials: D
authors.lastname: Rosmarin
mesh_terms: D000818:Animals; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000276:immunology; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D018793:Interleukin-13 / Q000037:antagonists & inhibitors* / Q000276:immunology; D015847:Interleukin-4 / Q000037:antagonists & inhibitors* / Q000276:immunology
chemical_list: C578095:IL13 protein, human; C508598:IL4 protein, human; D018793:Interleukin-13; D015847:Interleukin-4